I would be grateful from some advice from more experienced investors - I'm very much a novice! Regarding this share, what does a status of 'mandatory trading' mean on the London Stock Exchange website? Secondly, why does the price of this share change so little? E.g. on Google finance it hasn't updated since this morning. Is there a reason for that, beyond a technical fault with that site?
"Chablis"? Hmph - that's for communists! Burgundy is so passé. Now coal tar cordial is where it's at. More seriousl I cannot think of a semi-fledgling company trading on a public exchange today with more potential (commercial and - by virtue of the nature of their products - philanthropic) than AVCT. May be a bumpy ride, though, given cashflow requirements, but at least most of the R & D has been completed successfully.
Excellent post PP and that's what most reasonable people think in this country at the moment. Lemonaider you are also right in stating that Avacta has failed to make any money to date, but I have visited the company and met with Alastair Smith and believe me when I say that He is a seriously clever guy and a shrewd businessman and I still maintain that in 2014 you could easily double or triple your money, you just need a bit more patience. I've been here since 2009 and fully confident that I will be rewarded for sticking with Avacta.
Launch of Sensipod - First Point of Care Test Thu, 26th Sep 2013 07:00 RNS Number : 9171O Avacta Group PLC 26 September 2013
26 September 2013
Avacta Group plc
Launch of the Sensipod in-clinic blood testing system for vets
First point of care test to provide a canine environmental allergy pre-screen
Avacta Group plc (AIM: AVCT), a provider of diagnostic tools, consumables and reagents used in human and animal healthcare, announces that it has launched its in-clinic blood analysis system, Sensipod, to veterinary practices in the UK along with the first point of care test to screen dogs for environmental allergies.
Sensipod is an in-clinic diagnostic system designed to detect a wide range of markers of disease by rapidly carrying out an enzyme linked immunosorbent assay (ELISA) test - the gold standard for diagnostic tests - on a small sample of blood. The system is being launched in the UK with its first test, a canine environmental allergy pre-screen that assists the veterinarian in identifying allergies in dogs. Avacta is currently developing a large panel of additional tests for Sensipod covering common diseases in dogs, cats and horses, as well as other novel tests, which will provide a unique bench-top diagnostic capability for the veterinarian.
At the heart of the Sensipod system is an innovative single use cartridge, pre-loaded with test specific reagents, and the Sensipod bench-top instrument. The single use cartridge is capable of carrying out all of the steps of an ELISA test without any additional user interaction and provides a sensitive measure of disease biomarkers. When the full panel of tests is complete the Sensipod will equip vets with a state-of-the-art device that will provide a quick and easy diagnosis of some of the most common companion animal diseases.
The Sensipod in-clinic system complements Avacta's established reference laboratory diagnostic services which it provides to veterinarians in the UK, and its diagnostic test kits which it provides to third party reference laboratories globally. The programme of expansion of the Sensipod test menu will also generate new laboratory tests and diagnostic kits to expand the existing offering in these routes to market.
Alastair Smith, Chief Executive of Avacta Group said:
"I am absolutely delighted that Sensipod has now launched and is in the hands of veterinarians. A huge amount of hard work and innovation has delivered a product that we believe has massive potential in the veterinary market. Growth of the test menu is key to realising that potential. We are making good progress in that area and anticipate reporting the launch of a number of new tests during this financial year. Our initial focus for commercialisation of Sensipod is the UK and we have plans to address other geographical markets as the test menu grows.
"New reference laboratory tests and diagnostic kits
Lemonaider I can understand your irritation at the notion that you should feel warm inside even if AVCT shares fall. I totally agree with you.....most of us buy shares to generate a tangible, worthwhile profit, in my case to supplement my retirement income. In post-Blairite Britain we are unfortunately still surrounded by all these Chablis socialists who want to eat their fair trade chocolate, drive Citroens, work for Quangos and bask in political correctness! Some of them can clearly well afford to feign the concept of making money! There's plenty of them at Brighton this week.
Rest assured, beyond all the hype, Avacta continues to come across as an excellent company engaged in solid, globally valuable and highly marketable technology. They appear to be very well managed by a highly experienced and diverse board of directors which they continue to expand. Above all, they appear to remain on course as a good medium to long term investment. And there may be the rub....in today's stressed-out, impatient world, the barrow boy traders of the 80's who now run (infest) many of the UK's investment banks are often only really interested in the short term? I am confident that the majority of small to medium investors in Avacta together with its major share holders, will continue to retain their position for the next two to five years, at least. Good Luck for the future and...stick with them. I'm sure it will be worth it!!
With all due respect to Sukithedog, if I want to feel good about myself, I'll donate to charity directly. When I buy shares my aim is to make money, and all hype aside, this company has gloriously failed to do so yet. Sorry.
Datafeed and UK data supplied by NBTrader and Digital Look.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.